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Abstract 56 
 57 
Psychosis (delusions or hallucinations) in Alzheimer’s disease (AD+P) occurs in up to 50% of 58 
individuals and is associated with significantly worse clinical outcomes.  Atypical 59 
antipsychotics, first developed for schizophrenia, are commonly used in AD+P, suggesting 60 
shared mechanisms.  Despite this implication, little empirical research has been conducted to 61 
examine whether there are mechanistic similarities between AD+P and schizophrenia.  In this 62 
study, we tested whether polygenic risk score (PRS) for schizophrenia was associated with 63 
AD+P.  Schizophrenia PRS was calculated using Psychiatric Genomics Consortium data at 64 
10 GWAS p-value thresholds (PT) in 3,111 AD cases characterized for psychosis using 65 
validated, standardized tools.  Association between PRS and AD+P status was tested by 66 
logistic regression in each cohort individually and the results meta-analyzed.  The 67 
schizophrenia PRS was associated with AD+P at an optimum PT of 0.01.  The strongest 68 
association was for delusions where a one standard deviation increase in PRS was associated 69 
with a 1.18-fold increased risk (95% CI: 1.06-1.3; p=0.001).   These new findings point towards 70 
psychosis in AD – and particularly delusions – sharing some genetic liability with schizophrenia 71 
and support a transdiagnostic view of psychotic symptoms across the lifespan. 72 
 73 
 74 
Key words: psychosis, Alzheimer’s disease, genetics, delusions, hallucinations.  75 
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1. Introduction 76 
  77 
Psychosis in Alzheimer’s disease (AD+P) - broadly comprising delusions and hallucinations - 78 
is experienced by up to 50% of people over the course of the illness, with prevalence peaking 79 
in the later stages 1.  AD+P is associated with accelerated cognitive decline (independent of 80 
disease duration), higher mortality rates and distress to both people with the disease and their 81 
carers 2-4.  Moreover, there are wider societal implications with long-term follow up studies 82 
indicating that AD+P is associated with a shorter time to nursing home care 5.  Despite these 83 
compelling reasons for effective management, there is a critical treatment gap, with no 84 
licensed treatments available in many jurisdictions.  Atypical antipsychotics – developed first 85 
for schizophrenia – are frequently used to treat AD+P (in many countries off label) and, while 86 
they have some modest benefits, are associated with considerable harms, including a 1.5- to 87 
1.8-fold increase in mortality and a 3- fold increase in stroke 6.   88 
 89 
Clinically useful alternatives to antipsychotics are scarce. There are only two new 90 
antipsychotic compounds in phase II or later stages of development (pimavanserin and MP-91 
101) but both are refinements of existing mechanisms of action of atypical antipsychotics 92 
targeting mechanisms relevant to schizophrenia (e.g. 5HT2A, mGluR2/3) and side effects 93 
remain a concern7.  The limited understanding of the biological mechanisms underpinning 94 
AD+P represents a major challenge to the effective targeting of existing treatments and the 95 
identification of novel treatment targets.   96 
 97 
One key question is whether some or all of the psychotic symptoms experienced by people 98 
with AD have a similar basis to schizophrenia.  Phenomenologically the psychotic symptoms 99 
in each are different; in AD visual hallucinations are more common than auditory 100 
hallucinations, delusions are usually simple, and the so-called first rank symptoms of 101 
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schizophrenia are very rare.  In addition, schizophrenia is characterized by both positive and 102 
negative symptoms.  While negative symptoms can also accompany psychosis in AD 103 
consensus is yet to be reached on whether these other neuropsychiatric symptoms form part 104 
of the AD+P clinical syndrome.  Despite the different phenomenology, atypical antipsychotics 105 
confer some treatment benefits in some cases of AD+P 8, and similar neuropsychological 106 
deficits in processing speed and executive function have been observed in individuals with 107 
very-late-onset schizophrenia-like psychosis and AD+P9, suggesting some overlap. 108 
 109 
A transdiagnostic hypothesis, proposing a mechanistic overlap between AD+P and 110 
schizophrenia, is gaining some traction 10 and is supported by genetic studies of psychosis in 111 
adolescence, the general adult population and Huntington’s disease all showing overlap with 112 
schizophrenia 11-13.  In view of these findings and the high heritability of schizophrenia 14 and 113 
of AD+P (estimated at 81% and 61% respectively) 15, it is logical to look for common genetic 114 
underpinnings of the two disorders.  Comparative studies examining common mechanisms 115 
between AD and schizophrenia point towards synaptic elimination and disruption, and 116 
telomere length 16-18, but studies examining AD+P specifically and schizophrenia are less 117 
common.  It is of note that a recent major GWAS reported a nominally significant genetic 118 
correlation between schizophrenia and AD 19.  It is possible that the presence of psychosis in 119 
the AD sample (which was unknown in this study) was contributing to part of the association, 120 
underscoring the need for dissection of the AD phenotype by psychosis status.  In a small 121 
study, a copy number variant (CNV) with significant overlap of a duplicated region implicated 122 
in schizophrenia and autism (16p11.2) was found in two of 440 AD+P cases but not in AD 123 
without psychosis, or in those with more occasional symptoms 20.  Linkage studies have also 124 
implicated regions of the genome in AD+P that have been identified in schizophrenia 21, 22.  125 
Another approach is to examine whether polygenic risk for schizophrenia, summarized in a 126 
score (the weighted sum of risk associated alleles) with better discrimination properties than 127 
single markers 23,  is associated with AD+P.  Work in this area is limited to only one recent 128 
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study which, surprisingly, reported that a genetic risk score comprising 94 SNPs reaching 129 
genome wide significance for association with schizophrenia was lower in AD+P compared 130 
with AD without psychosis 24.  While this study represents an important preliminary step in 131 
AD+P research, a full genome-wide polygenic risk score (PRS) approach is imperative to 132 
address this key question25, 26.   133 
 134 
Another largely unexplored avenue in AD+P genetic research relates to the split of delusions 135 
and hallucinations.  Although the two symptoms frequently co-occur in AD, there is evidence 136 
from longitudinal cohort studies indicating that 10-20% of people experience hallucinations 137 
without delusions and that the two symptoms are associated with different clinical outcomes 2, 138 
27, suggesting the presence of two distinct clinical phenotypes.  While it is commonplace to 139 
separate out composite psychotic symptoms in neuroimaging studies of AD+P 28, 29, their 140 
separate genetic associations have not yet been examined in any large-scale AD studies 141 
leveraging GWAS data 30.  This is a particularly relevant issue when assessing genetic overlap 142 
with schizophrenia where the emerging evidence from neuroimaging and the clinical similarity 143 
supports the hypothesis that shared etiology would be specific to delusions. 144 
 145 
We conducted an analysis of the relationship between genetic liability for schizophrenia and 146 
AD+P with two principal objectives; firstly, we tested whether a PRS for schizophrenia was 147 
associated with AD+P and secondly, we examined the association of the PRS with AD+P 148 
stratified to focus on delusions. 149 
 150 
2. Methods 151 
 152 
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Ethical approval for this analysis protocol was obtained from University of Exeter Medical 153 
School Research Ethics Committee (Nov17/D/143).   154 
 155 
2.1 Cohorts 156 
AD+P target data consisted of 3,111 AD cases from 11 cohort studies in Europe and the USA:  157 
AddNeuroMed 31 (Europe, longitudinal: assessment every three months for maximum 1 year), 158 
Alzheimer’s Disease Neuroimaging Initiative 32 (ADNI; USA, longitudinal: assessment 159 
baseline, 6, 12, 24 and 36 months for maximum 3 years), Istituto di Ricovero e Cura a 160 
Carattere Scientifico (IRCCS 1; Italy, cross sectional), Health and Memory Study in Nord-161 
Trøndelag 33 (HMS; Norway, cross sectional), Resource Use and Disease Couse in Dementia 162 
34 (REDIC; Norway, longitudinal: assessment every 6 months for maximum 2.5 years), 163 
Norwegian registry of persons assessed for cognitive symptoms 35 (NorCog; Norway, cross 164 
sectional), Samhandling mellom avdeling for alderspsykiatri og kommunale sykehjem (SAM-165 
AKS; Norway, cross sectional), The Dementia Study in Northern Norway 36 (NordNorge, 166 
Norway, longitudinal: assessment baseline and 1 year), Progression of Alzheimer’s Disease 167 
and Resource Use 37 (PADR; Norway, longitudinal: assessment baseline and 1 year), The 168 
Dementia Study in Western Norway 38 (DemVest; Norway, longitudinal: assessment every 12 169 
months maximum 6 years); and data from the National Alzheimer’s Coordinating Center 170 
(NACC; USA, longitudinal: assessment approximately every 12 months) and the National 171 
Institute on Aging Genetics Data Storage Site (NIAGADS), Table 1).  Full cohort details are 172 
contained in the supplementary material and the Norwegian cohorts are also described in the 173 
latest GWAS of Alzheimer’s disease 39.  Informed consent was obtained by each study for all 174 
participants. 175 
 176 
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Some data used in the preparation of this article were obtained from the Alzheimer’s Disease 177 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 178 
as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The 179 
primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), 180 
positron emission tomography (PET), other biological markers, and clinical and 181 
neuropsychological assessment can be combined to measure the progression of mild 182 
cognitive impairment (MCI) and early Alzheimer’s disease (AD).  For up-to-date information, 183 
see www.adni-info.org. 184 
 185 
2.2 AD clinical assessments 186 
 187 
Diagnosis of AD was performed according to ICD-10 etiological diagnosis, NINCDS-ADRDA 188 
criteria or clinical diagnosis by psychiatrist or geriatrician.  Longitudinal data was available for 189 
7 cohorts (ADNI, AddNeuroMed, DemVest, NordNorge, PADR, REDIC, NACC) and psychotic 190 
symptom classification was on the maximum amount of follow up data available.  Any cases 191 
with a history of bipolar disorder or schizophrenia were excluded.  For NorCog, PADR, REDIC, 192 
SAM-AKS, NACC and ADNI the necessary information on psychiatric history was extracted 193 
from source study data resulting in 3, 1, 2, 1, 31 and 1 exclusions respectively.  For 194 
AddNeuroMed, DemVest, IRCCS 1 and NordNorge this was an exclusion criterion applied at 195 
entry to those individual studies.  No information about psychiatric history was available for 196 
the HMS study.  Dementia severity was assessed in all cohorts by Mini Mental State 197 
Examination (MMSE) and psychotic symptoms were assessed by the Neuropsychiatric 198 
Inventory (NPI) or its short version, the Neuropsychiatric Inventory Questionnaire (NPI-Q), 199 
they are among the most widely used validated instruments to assess psychosis40.  Psychotic 200 
symptoms are rated on the basis of items A (delusions) and B (hallucinations) of the NPI and 201 
NPI-Q. These are two different versions of the same scale, which are strongly correlated and 202 
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have good between-rater and test-retest reliability, particularly for the psychosis items 31, 43.  203 
Ratings were carried about by trained research staff in all cases.  In the full NPI, 204 
neuropsychiatric symptoms are coded as present or absent first.  If rated present they are 205 
further scored according to their frequency (1-4) and severity (1-3) with the resulting scores 206 
multiplied to give an overall rating (i.e. possible scores are 1,2,3,4,6,8,9 and 12 with 0 207 
indicating no symptoms).  The NPI-Q is rated only on a scale of 0 to 3 according to the severity 208 
of the symptom.  Both scales have been designed to be completed by verbal interview with a 209 
proxy informant who knows the person with AD well.  Several diagnostic criteria for AD+P 210 
have been proposed but none have been adopted clinically, meaning that where in other 211 
psychiatric disorders medical records can be screened, in AD+P this would be unreliable and 212 
ratings on specific validated assessment scales must be used.  Using such scales, we thus 213 
undertook examination of three related but progressively more homogenous psychotic 214 
phenotypes:  215 
 216 
1. Psychosis wide: Psychosis present: the presence of delusions or hallucinations (>0) 217 
at any point; No psychosis: no evidence of delusions or hallucinations at any point in 218 
follow up.   219 
 220 
2. Psychosis narrow: Psychosis present: the presence of delusions or hallucinations (>0) 221 
at any point; No psychosis: here, an additional level of screening was applied to those 222 
rated as having no delusions or hallucinations.  In these cases, if an individual was 223 
psychosis-free based on criteria for psychosis wide but had not yet reached a 224 
moderately-severe dementia stage based on available data (defined as MMSE<20) 225 
they were excluded from the analysis.  This is a similar approach to that used in most 226 
previous AD+P genetic research 24, 41. 227 
 228 
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3. Delusions narrow: Delusions present: the presence of delusions (>0) at any point 229 
during follow up.  Thus, the delusion group was the psychosis group above with any 230 
individuals rated as having hallucinations only removed.  No delusions: as per 231 
psychosis narrow.    232 
 233 
2.3 Genotyping and QC 234 
 235 
The genotyping chips used are detailed in Table 1.  Raw genotype data for individual cohorts 236 
underwent appropriate QC steps (implemented in PLINK).  SNPs with a minor allele frequency 237 
≤5% and a Hardy Weinberg equilibrium p < 10−5 were excluded.  The SNP and individual 238 
genotype failure threshold was set at 5% and individuals with mean heterozygosity ±3 239 
standard deviations were excluded.  The analysis was restricted to individuals of European 240 
ancestry using genetic principal components computed by EIGENSTRAT.  Related (pi-hat 241 
>0.2) or duplicate individuals both within and between cohorts were excluded.  Phasing 242 
(EAGLE2) and imputation (PBWT) was done via the Sanger Imputation Service using the 243 
Haplotype Reference Consortium (r1.1) reference panel on all cohorts.  After imputation only 244 
SNPs with an imputation quality (INFO) score >0.4 and MAF >0.05 were retained.  This 245 
resulted in 4,895,913 SNPs common across all eleven cohorts available to compute polygenic 246 
risk scores. 247 
 248 
The most recently published schizophrenia GWAS data from the Psychiatric Genomics 249 
Consortium (PGC) was used as base data to generate PRS in the target AD sample 26. SNPs 250 
with MAF<0.1, INFO<0.9 and indels were excluded from the base dataset to leave only the 251 
most informative SNPs and only one SNP from the extended MHC region was included 42.  As 252 
a positive control and to evaluate the specificity of the association we then generated PRS of 253 
height and depression using the latest GIANT consortium and PGC GWAS results 43, 44. 254 
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 255 
2.4 Analysis 256 
 257 
PRS for schizophrenia were generated in PRSice 45 at the following 10 GWAS p-value 258 
thresholds (PT): 5x10-8, 1x10-5, 1x10-4, 1x10-3, 0.01, 0.05, 0.1, 0.2, 0.5 and 1.  Clumping was 259 
performed (250kb, r2>0.1) to retain only the SNP with the strongest association in each 260 
window.  The resulting PRS were standardized (centering by mean, scaling by standard 261 
deviation) for the analysis. 262 
 263 
Power was calculated using AVENGEME46, with schizophrenia parameters as set out in Palla 264 
and Dudbridge46, number of markers genotyped in both datasets was 76,213 (see section 265 
3.1), a prevalence of 40%1 and of 36%1 was used for psychosis and delusions, and case 266 
control sample fractions as per Table 2.  There is no data available for estimated covariance 267 
between AD+P and schizophrenia but if this value is assumed to be 0.08 (less than the 0.13 268 
and 0.17 for schizophrenia and major depressive disorder and bipolar disorder estimated by 269 
AVENGEME46), this study has >=80% power for each PT>=0.01 for psychosis and delusions 270 
respectively but <80% power below this value.  All statistical analysis was implemented in R.  271 
For each cohort 10 logistic regression models (one per PT) were run with each of the previously 272 
defined psychosis phenotypes as the binary outcome and the first 10 ancestry principal 273 
components included as covariates.  Disease severity is accounted for in our ‘narrow’ 274 
phenotype definitions and as there is no strong evidence that age and gender are associated 275 
with AD+P1 so these were not included as covariates.  Logistic regression assumptions were 276 
confirmed using the R ‘car’ package.  Proportion of variance explained (R2) by PRS, on the 277 
observed scale, was determined by subtracting the Nagelkerke’s pseudo-R2 of the null model 278 
from that of the full model.  Regression coefficients for each PT across all cohorts were then 279 
included in random effects meta-analyses to account for between-study variation in data 280 
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collection protocols, frequency of psychosis and dementia severity 47-49.  Meta-analysis was 281 
undertaken using the ‘rma’ function in the ‘metafor’ package using the REML method 50.  282 
Because the PRS calculated were correlated a Bonferroni correction for multiple testing was 283 
considered too stringent.  Using a correlation matrix of the 10 PRS and the matSpD tool 284 
https://gump.qimr.edu.au/general/daleN/matSpD/), the effective number of independent tests 285 
was determined to be 5 and the experiment-wide significance threshold for type I error rate of 286 
5% determined to be p=0.01.  All tests reported are two-sided.  287 
 288 
3. Results 289 
 290 
On average across all eleven cohorts, individuals were in the mild-moderate stages of 291 
dementia at first assessment (mean MMSE of 19).  Mean MMSE by cohort ranged from an 292 
MMSE of 12 (IRCCS 1) to 24 (ADNI) and this was a correlate of the prevalence of psychosis 293 
in each cohort (note the denominator would be the overall cohort N in Table 1), with cohorts 294 
that contained individuals with more severe dementia typically having a higher proportion of 295 
people with psychosis.  Between cohorts, mean age at baseline ranged from 75 to 87 years 296 
and the proportion of male participants ranged from 26% to 59%.  There was little difference 297 
in age between the psychosis and no psychosis groups across all studies but gender 298 
distributions did differ.   299 
 300 
Frequency of the three phenotypes investigated by cohort is shown in Table 2.  Of the 3,111 301 
individuals screened, 1,116 (36%) had psychosis (wide definition group).  Of the 1,995 who 302 
were rated as having no psychosis based on their assessment scale result alone, 879 had not 303 
yet reached the moderate stages of disease and so were excluded; 1,116 AD+P cases and 304 
1,116 AD no psychosis ‘controls’ were included in the analysis of the narrow phenotype of 305 
psychosis.  936 cases met the criteria for having delusions narrow. 306 
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 307 
3.1 Schizophrenia PRS is associated with AD psychosis status 308 
 309 
After clumping, 76,213 independent variants were available for computing PRS.  Random 310 
effects meta-analysis across the 11 cohorts showed the largest OR for the schizophrenia PRS 311 
was at PT=0.01 and this was significantly associated with symptom status across the 312 
psychosis wide, psychosis narrow and delusions narrow phenotypes despite the progressively 313 
smaller sample size in each of these groups (OR: 1.14 95% CI:1.05-1.23, p=0.003; OR: 1.16 314 
95% CI:1.06-1.28 p=0.004; OR: 1.18 95% CI:1.06-1.30, p=0.001 respectively), see Figure 1 315 
and Table 3.  PRS was also significantly associated with both the psychosis narrow and 316 
delusions narrow phenotypes at every PT >0.01.  The largest effect size was observed in the 317 
delusions narrow group.  Overall, there was no evidence of significant heterogeneity; I2 318 
statistics were close to 0% for PT =0.01 across the three phenotypes. 319 
 320 
In the individual cohort analysis, we observed that the effect estimates of association between 321 
schizophrenia PRS and AD+P in nine of the 11 studies were in the same direction (OR>1); 322 
albeit not statistically significantly (Supplementary Table 1).  A forest plot of individual study 323 
estimates for delusions narrow at PT=0.01, the strongest association found in the above meta-324 
analysis, is shown in Figure 2.  A similar plot at PT=1 for comparison is shown in the 325 
Supplementary material along with plots for psychosis wide and psychosis narrow 326 
phenotypes.  The highest Nagelkerke’s R2 estimate was 2.9% (AddNeuroMed) and the lowest 327 
was <0.1% (IRCCS 1).  An overall variance explained (Nagelkerke’s R2) in AD+P by 328 
schizophrenia PRS of 0.08% was estimated by calculating the weighted average R2 across 329 
the 11 studies.  To determine the specificity of the signal, PRS for major depression (using the 330 
PGC GWAS44) and height (GIANT consortium GWAS43) were generated post-hoc at PT=1 and 331 
tested for association with delusions using the same procedure as described in Section 2.4.  332 
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Neither PRS showed any evidence of association (major depression: OR: 1.03, 95% CI: 0.91-333 
1.18, p=0.61; height: OR: 0.99, 95% CI: 0.85-1.17, p=0.99). 334 
 335 
4. Discussion  336 
 337 
We set out to examine whether genetic risk for psychotic symptoms in AD (AD+P) is 338 
attributable to common schizophrenia variants.  Using polygenic scoring, we found that 339 
schizophrenia PRS was associated with AD+P in a collection of over 3,000 well characterized 340 
cases and the association persisted as the AD+P phenotype was more precisely defined 341 
resulting in a smaller N.  The largest effect size was observed at PT=0.01 which was 342 
associated with a 1.14, 1.16 and 1.18-fold (per standard deviation increase in PRS) increased 343 
risk of psychosis (wide), psychosis (narrow) and delusions (narrow) respectively.  In the 344 
individual cohort analysis, the odds ratios of nine of the eleven studies were in the same 345 
direction (OR>1).  In all, these new findings suggest that AD+P is part of a spectrum of 346 
neuropsychiatric conditions characterized by psychosis across the lifespan but in common 347 
with other PRS studies in psychiatric genomics are yet not appropriate for symptom or disease 348 
course prediction.  Although the variance explained by schizophrenia PRS in AD+P is only 349 
modest, with the R2 estimates being less than 1%, this should be seen in the context of the 350 
same PRS explaining around 2.5% of the variance in bipolar disorder and 1% in MDD in a 351 
cross-disorder analysis of the Psychiatric Genomics Consortium with significantly larger target 352 
sample sizes 51.   353 
 354 
In line with our findings, a recent study in UK Biobank, found psychotic experiences in the 355 
general population to be associated with PRS for schizophrenia, with the strongest association 356 
observed for delusions 12.  Several possible conclusions can be drawn from the finding that 357 
the association was still observed in the delusions phenotype in this study, despite a 358 
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considerably smaller N compared with the psychosis phenotypes.  This finding may point 359 
towards a subset of AD+P patients that have a more schizophrenia-like phenotype.  More 360 
work is needed to investigate whether further diagnostic refinements to AD+P syndrome 361 
definitions are necessary, which may provide a more robust approach for pharmacological 362 
intervention trials.  Related to this, from a methodological point of view, we show that there is 363 
a need for future studies in AD to consider delusions and hallucinations separately.  We cannot 364 
rule out a genetic association between hallucinations in AD and schizophrenia in these cohorts 365 
but the evidence at present suggests a weaker association than for delusions.  One might 366 
speculate that this is due to visual hallucinations in AD being more often the result of a broader 367 
range of causes (e.g. visual hallucinations due to medication or delirium) than delusions, thus 368 
introducing more noise into the phenotype.  The final wider implication is related to the 369 
schizophrenia PRS being associated with a broad spectrum of psychotic disorders and 370 
personality traits 11-13, 51-53.  Our findings support a transdiagnostic explanation of delusions, 371 
which reaches into neurodegenerative disease and is underpinned by a degree of common 372 
genetic liability. 373 
 374 
A key strength of our study is the detailed phenotyping with longitudinal data being available 375 
in seven of the eleven cohorts.  Rather than relying on medical record screens, which would 376 
be highly unreliable for AD+P given the lack of universally accepted and used diagnostic 377 
criteria, every individual in our analysis was assessed using specific, reliable assessment 378 
tools.  We then used this data to dissect AD+P phenotype genetics for the first time by focusing 379 
on delusions as well as the broader syndrome.  We also followed previous research by taking 380 
extra measures to screen the ‘control’ groups.  This removed any cases in the mild stages of 381 
disease who had not yet developed symptoms (i.e. those still at risk 1).  This approach has 382 
been used in most previous genetic research but our extension to focus on delusions in AD+P 383 
is novel.  Our finding that this more precision definition the phenotype strengthened the 384 
association is consistent with genetic studies of other polygenic traits, like depression 44.   385 
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 386 
For one study (HMS) data on history of major psychiatric conditions were not available.  It is 387 
possible that some individuals with schizophrenia were present in this cohort however HMS is 388 
a cohort with a mean age of 87 so it is highly unlikely that the number would be more than one 389 
or two out of 178 people in the HMS cohort (this is also supported by the very small numbers 390 
we found among the other studies we screened).  With over 3,000 samples, this is, to our 391 
knowledge, the largest analysis of AD+P to exploit GWAS data 41.  We acknowledge that using 392 
different cohorts has led to some variability due to sampling but it is important to acknowledge 393 
that there are no single cohorts which are large enough to conduct an analysis of this kind and 394 
because of potential sampling and protocol variations across the individual studies we ensured 395 
an appropriate analysis was implemented to account for this variability; the same approach as 396 
used in other studies examining PRS in complex phenotypes 47-49.  We had access to raw 397 
individual-level clinical and genotype data, allowing us to run the same regression models in 398 
each study.  This included undertaking the same QC across cohorts, imputing all chip data to 399 
the same reference panel and analyzing only SNPs present across all cohorts.   After ensuring 400 
this standardized process was followed for each cohort we ran a random effects meta-401 
analysis, allowing for the effect of the PRS on AD+P to vary across studies.  In all, and in the 402 
absence of a single large enough study, these measures provide the most robust estimates, 403 
as reflected in the low heterogeneity statistics of the meta-analysis and the narrow range of 404 
effect estimates and overlapping confidence intervals across the eleven studies included 405 
(Figure 2 and Supplementary figures 1-3).  Finally, as with all similar studies, these results are 406 
not generalizable to individuals with non-European ancestry; there is an equal imperative to 407 
extend the genomics of AD+P to other populations as in AD itself.   408 
 409 
A previous study which examined a genetic risk score at a more conservative PT comprised of 410 
only 94 genome-wide significant schizophrenia SNPs found it to be lower in AD+P cases24.  411 
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Our study is a similar size to this previous study, and the NACC data was used in both.   Given 412 
that a PRS with only 94 SNPs will be a less powerful predictor than a full genome-wide score 413 
it is possible larger studies will be needed to confirm associations at this more conservative 414 
PT.  Nevertheless, schizophrenia is highly polygenic; tens of thousands of markers explain 415 
only 7% of the variance on the liability scale, while for optimum cross-trait case-control (e.g. 416 
schizophrenia and bipolar) prediction many thousands more SNPs are required51.  In addition, 417 
cases of schizophrenia in the PGC study (used as base sample to estimate PRS), include 418 
patients with both a positive and negative syndrome. There is evidence that negative and 419 
disorganized symptoms are more heritable than positive, which – although we report a positive 420 
association – may reduce the power of schizophrenia PRS at more conservative PT to 421 
discriminate AD cases with or without psychotic symptoms 54, 55.  Accordingly, a full account 422 
of association between schizophrenia and AD+P should exploit the full polygenic nature of 423 
schizophrenia; our study is the first to do this and the findings represent an important further 424 
step towards a complete account of the relationship between common schizophrenia variants 425 
and AD+P.  Another important milestone will be an appropriately powered discovery GWAS 426 
of AD+P and all of these points underscore the need for increasing samples sizes in this field.  427 
 428 
In summary, these findings support shared genetic liability between schizophrenia and 429 
delusions in AD. This provides a strong rationale for further work to build a clearer clinical and 430 
biological understanding of the psychosis syndrome in AD, an urgently needed step for better 431 
management and treatment development. 432 
  433 
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Table 1: Baseline characteristics by cohort 708 
  N 
Age 
  
Gender 
  
MMSE  
  Scale   
Follow 
up 
(years)*+   
Number of 
assessments 
done+   Array 
  
AD-P AD+P 
 
AD-P AD+P  AD-P AD+P 
          
    Mean SD Mean SD   % male % male   Mean SD Mean SD                 
AddNeuroMed 225 76 7 78 5.6 
 42 24  21 4.6 20 4.8  NPI  1  5  Illumina 610 
ADNI 248 76 7.2 74 7.4 
 63 43  24 2.5 23 2.5  NPI-Q  3  4  Illumina OmniExpress 
DemVest 80 77 8.3 76 5.5 
 23 38  24 2.4 23 2.4  NPI  5  6  Illumina OmniExpress 
IRCCS 1 326 78 7.4 79 6.4 
 44 36  14 6.1 10 6.3  NPI  0  1  Illumina GSA 
HMS 178 86 6.2 86 7.6 
 24 28  14 6.8 12 6.0  NPI  0  1  Illumina OmniExpress 
NorCog 563 74 9.1 77 8.2 
 43 39  22 4.2 21 4.6  NPI-Q  0  1  Illumina OmniExpress 
NordNorge 133 80 6.7 83 6.2 
 42 36  24 4.3 22 4.5  NPI  1  2  Illumina OmniExpress 
PADR 106 76 6.6 77 6.6 
 35 30  21 4.3 21 4.4  NPI-Q  1  2  Illumina OmniExpress 
REDIC 323 86 6.9 84 7.4 
 35 32  17 6.4 16 6.5  NPI  2  5  Illumina OmniExpress 
SAM-AKS 93 86 6.8 86 5 
 29 38  16 5.0 
15 5.2  NPI  0  1  Illumina OmniExpress 
NACC 836 79 7.8 78 9  54 44  20 7.1 19 7.0  NPI-Q  2  3  Illumina 660/Omni Express 
TOTAL 3111 79 8.7 80 8.2   44 37   20 6 18 6.8   -   -   -   - 
          
           
 
         
NPI: Neuropsychiatric Inventory (full version); NPI-Q: Neuropsychiatric Inventory- Questionnaire; MMSE: Mini Mental State Examination 709 
*'0' denotes that the study was cross sectional (i.e. one assessment available) 710 
+figures are median 711 
 712 
  713 
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Table 2: Frequencies of symptoms by cohort for the three psychosis phenotypes 714 
  Psychosis wide   Psychosis narrow   Delusions narrow 
 N  Absent  Present  N  Absent  Present  N  Absent  Present 
      n %   n %       n %   n %       n %   n % 
AddNeuroMed 225  133 59 
 92 41  157  65 41  92 59  142  65 46  77 54 
ADNI 248  183 74 
 65 26  117  52 44  65 56  99  52 53  47 47 
DemVest 80  30 38 
 50 63  75  25 33  50 67  69  25 36  44 64 
IRCCS 1 326  222 68 
 104 32  293  189 65  104 35  271  189 70  82 30 
HMS 178  107 60 
 71 40  162  91 56  71 44  152  91 60  61 40 
NorCog 563  402 71 
 161 29  288  127 44  161 56  260  127 49  133 51 
NordNorge 133  105 79 
 28 21  45  17 38  28 62  38  17 45  21 55 
PADR 106  62 58 
 44 42  83  39 47  44 53  80  39 49  41 51 
REDIC 323  158 49 
 165 51  276  111 40  165 60  265  111 42  154 58 
SAM-AKS 93  73 78 
 20 22  80  60 75  20 25  75  60 80  15 20 
NACC 836  520 62 
 316 38  656  340 52  316 48  601  340 57  261 43 
                        
TOTAL 3111   1995 64   1116 36   2232   1116 50   1116 50   2052   1116 54   936 46 
 715 
Percentages may not sum to 100 due to rounding. 716 
  717 
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Table 3: Random effects meta-analysis results for association between schizophrenia PRS across 10 GWAS thresholds (PT) and 718 
AD+P. 719 
      Psychosis wide   Psychosis narrow   Delusions narrow 
PT nSNPs   OR 95% CI P   OR 95% CI P   OR 95% CI P 
5x10-08 125  1.04 0.96 - 1.13 0.32  1.01 0.92 - 1.10 0.89  1.03 0.94 - 1.14 0.48 
1x10-05 511  1.07 0.98 - 1.16 0.15  1.06 0.97 - 1.16 0.20  1.06 0.97 - 1.17 0.20 
1x10-04 1147  1.07 0.96 - 1.18 0.21  1.07 0.96 - 1.19 0.21  1.07 0.96 - 1.18 0.21 
1x10-03 2,922  1.09 0.98 - 1.21 0.11  1.10 0.98 - 1.22 0.10  1.09 0.98 - 1.21 0.10 
0.01 8,709  1.14 1.05 - 1.23 0.003  1.16 1.06 - 1.28 0.002  1.18 1.06 - 1.30 0.001 
0.05 19,656  1.12 1.03 - 1.22 0.01  1.13 1.02 - 1.24 0.02  1.14 1.03 - 1.26 0.01 
0.1 28,143  1.11 1.01 - 1.21 0.02  1.12 1.02 - 1.24 0.02  1.15 1.04 - 1.28 0.01 
0.2 40,253  1.10 1.01 - 1.20 0.04  1.12 1.01 - 1.24 0.03  1.14 1.02 - 1.26 0.02 
0.5 61,727  1.10 1.00 - 1.22 0.04  1.13 1.02 - 1.25 0.02  1.15 1.03 - 1.28 0.01 
1 76,213   1.10 0.99 - 1.23 0.08   1.13 1.02 - 1.25 0.02   1.14 1.03 - 1.27 0.02 
OR: Odds ratio; odds ratio estimates may differ slightly from those represented in Figure 1 due to rounding 720 
  721 
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Figure 1: Odds ratios from random effects meta-analysis of AD psychosis wide, narrow and delusions narrow association with 722 
schizophrenia PRS.  Each bar represents PRS composed of markers at 10 different schizophrenia GWAS p-value thresholds (PT).  P-723 
values shown above each bar 724 
 725 
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Figure 2: Forest plot of meta-analysis of delusions narrow for PRS calculated at PT=0.01 (i.e. 8,709 SNPs).  Overall estimate from random 726 
effects model is represented by the diamond below the individual study estimates. 727 
 728 
 729 
